Dechra Veterinary Products announces it has received FDA approval to market EQUIDONE Gel, which contains the active ingredient domperidone.
EQUIDONE Gel is a patent protected new animal drug approval (NADA) and the only FDA approved product to prevent fescue toxicosis in periparturient mares. Each 25 cc EQUIDONE Gel syringe contains 2.75 grams of domperidone, which will provide treatment for an 1100 lb mare for five days. EQUIDONE Gel is an oral gel to be administered daily 10-15 days prior to the expected foaling date and can be continued for up to five days post foaling.
"The approval of EQUIDONE is exciting news for Dechra and further enhances our specialized equine product portfolio," says Mike Eldred, President of US Operations for Dechra. "Our sales and marketing teams are gearing up to launch EQUIDONE at the Annual Association of Equine Practitioners meeting in December. We anticipate product to be available through our network of distribution partners in late October."
Press Release